Jun 05, 2019 / 03:30PM GMT
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity Analyst
All right. We're going to go ahead and get started because I want all of 30 minutes here for my discussion with Mr. O'Day. But as you know, I'm really excited and happy to have the new Chairman and CEO of Gilead Sciences up here with me, Mr. Daniel O'Day. Great to have you here with us on your first investor coming-out session to meet the -- to meet all of Wall Street.
Questions and Answers:
Michael Jonathan Yee - Jefferies LLC, Research Division - Equity AnalystNow of course, you know most people on Wall Street from your time at Roche, but now that you've had some time to settle in at Gilead, maybe just talk to us about how it's been. What have you been focused on at Gilead in your time there? And obviously, what are you most focused on at Gilead over the foreseeable future? And we'll get in some of the details of that.
Daniel O'Day - Gilead Sciences, Inc. - Chairman & CEO
Yes, sure. So first of all, Michael, thank
Trustpilot
